Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (Q38178192)

30 August 2017

title

Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia (English)

1 reference

30 August 2017

1 reference

Philadelphia chromosome

1 reference

object named as

Philadelphia chromosome

2 August 2024

3

Greg L Plosker

1 reference

30 August 2017

Yahiya Y Syed

1

1 reference

30 August 2017

Paul L McCormack

series ordinal

2

1 reference

30 August 2017

language of work or name

1 reference

1 February 2014

1 reference

30 August 2017

1 reference

30 August 2017

volume

28

1 reference

30 August 2017

issue

1

1 reference

30 August 2017

page(s)

107-120

1 reference

Molecular biology of bcr-abl1-positive chronic myeloid leukemia

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Imatinib: a review of its use in chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Management of chronic myeloid leukaemia in clinical practice in France: results of the French subset of patients from the UNIC study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Nilotinib: in the first-line treatment of newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Activated Ca2+/calmodulin-dependent protein kinase IIgamma is a critical regulator of myeloid leukemia cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Evaluation of the pharmacokinetics and safety of bosutinib in patients with chronic hepatic impairment and matched healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

A clinical study to examine the potential effect of lansoprazole on the pharmacokinetics of bosutinib when administered concomitantly to healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Pharmacokinetic-pharmacodynamic relationship of bosutinib in patients with chronic phase chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Current concerns of undertreatment and overtreatment in chronic myeloid leukemia based on European LeukemiaNet 2013 recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

Abl kinases are required for vascular function, Tie2 expression, and angiopoietin-1-mediated survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40259-013-0082-X

10.1007/S40259-013-0082-X

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference